Startup Funding Tracker
Home›Companies›Healthcare›BioVentrix

Bioventrix, Inc.

Develops an investigational heart device for surgeons treating patients with heart failure.

ActiveHealthcare · Medical devices
Updated Nov 9, 2026·Latest SEC filing Oct 8, 2026·Suggest an edit

About BioVentrix

BioVentrix is a private company based in Mansfield, Massachusetts. It has reported $171,706,846 raised in 23 offerings on Form D since October 2009. Its chief executive is Steven Chartier.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 29, 2026Oct 8, 2026$1,200,000of $3.0M target6$200KDebt, Options, Securities on exerciseRule 506(b)Form D ↗
Apr 16, 2026Apr 24, 2026amended Sep 9, 2026$2,965,000of $10.0M target25$118KSecured Convertible Promissory NotesRule 506(b)Form D/A ↗2 earlier filings
Oct 10, 2024Oct 15, 2024amended Nov 4, 2025$6,672,600of $12.0M target45$148KSECURED CONVERTIBLE PROMISSORY NOTESRule 506(b)Form D/A ↗2 earlier filings
Mar 22, 2024Mar 29, 2024amended Aug 29, 2024$3,000,000fully sold21$142KEquity, SECURED CONVERTIBLE PROMISSORY NOTESRule 506(b)Form D/A ↗1 earlier filing
Mar 30, 2023Apr 4, 2023$12,650,000of $15.6M target12$1.0MEquityRule 506(b)Form D ↗
Jan 13, 2023Jan 25, 2023$1,977,000of $3.0M target18$109KCONVERTIBLE NOTESRule 506(b)Form D ↗
Apr 1, 2022Apr 6, 2022$1,000,000of $10.0M target1$1.0MEquityRule 506(b)Form D ↗
Jan 2, 2020Jan 6, 2020amended Nov 25, 2020$14,755,700of $25.0M target108$136KOptions, CONVERTIBLE NOTESRule 506(b)Form D/A ↗1 earlier filing
Jul 19, 2019Jul 26, 2019$2,549,200of $3.9M target1$2.5MEquity, OptionsRule 506(b)Form D ↗
Aug 25, 2017Aug 30, 2017amended Jul 23, 2019$40,000,000fully sold162$246KEquityRule 506(b)Form D/A ↗5 earlier filings
Jul 21, 2016Jul 26, 2016amended Jul 3, 2017$14,504,967fully sold152$95,427Equity, CONVERTIBLE NOTESRule 506(b)Form D/A ↗4 earlier filings
Dec 12, 2014Dec 19, 2014amended Dec 8, 2015$14,000,000of $17.5M target64$218KEquityRule 506(b)Form D/A ↗2 earlier filings
Jan 24, 2014Feb 6, 2014amended Jul 8, 2014$12,430,879fully sold195$63,748EquityRule 506(b)Form D/A ↗2 earlier filings
Dec 3, 2013Dec 13, 2013amended Jan 24, 2014$2,000,000fully sold4$500KEquity, Options, Securities on exerciseRule 506(b)Form D/A ↗1 earlier filing
Apr 12, 2013Apr 19, 2013amended Jul 12, 2013$6,539,187of $8.0M target115$56,862Equity06Form D/A ↗1 earlier filing
Nov 8, 2012Nov 21, 2012amended Jan 28, 2013$4,500,000fully sold109$41,284Equity06Form D/A ↗2 earlier filings
Apr 9, 2012Apr 23, 2012amended May 11, 2012$5,073,540of $7.0M target88$57,654Equity06Form D/A ↗1 earlier filing
Feb 22, 2012Mar 7, 2012$330,000of $6.0M target1$330KEquity06Form D ↗
Oct 31, 2011Nov 22, 2011$5,985,817of $10.0M target146$40,999Equity, Debt, Secured Promissory Notes convertible into the Issuer's Preferred Stock.06Form D ↗
Sep 23, 2011Oct 11, 2011$5,052,817of $10.0M target118$42,820Equity, Debt, Secured Promissory Notes convertible into the Issuer's Preferred Stock06Form D ↗
Aug 18, 2011Oct 11, 2011$5,052,817of $10.0M target118$42,820Equity, Debt, Secured Promissory Notes convertible into the Issuer's Preferred Stock06Form D ↗
Dec 30, 2010Jan 14, 2011amended Jul 28, 2011$3,867,817of $10.0M target90$42,976Equity, Debt, Secured Promissory Notes convertible into the Issuer's Preferred Stock.06Form D/A ↗3 earlier filings
Oct 3, 2009Oct 6, 2009amended Dec 16, 2010$5,599,505fully sold157$35,666Equity, Debt06Form D/A ↗3 earlier filings
Total, 23 offerings$171,706,846

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on BioVentrix's Form D filed Oct 8, 2026.

Steven Chartier
Steven Chartier
President and Co-Chief Executive Officer, director
LinkedIn ↗
Dave Richmond
Dave Richmond
Executive officer and director
LinkedIn ↗
Rishi Puri
Rishi Puri
Director
MR
Mark Ravich
Independent Board Member
Also a director at Dilon Technologies.
William Abraham

Earlier filings also listed Michael Taglich (director, last listed Nov 2025), William Abbott (chief financial officer, last listed Apr 2023), Rinda Sama (director, last listed Apr 2023), Raymond Cohen (director, last listed Apr 2023), Raphael Wisniewski (director, last listed Apr 2023), Ori Ben-Yehuda (executive officer, last listed Apr 2023), James Dillon (executive officer and director, last listed Apr 2023) and Christopher Wolff (executive officer, last listed Apr 2023).

Sources

  1. SECBIOVENTRIX, INC. Form D/A, filed Sep 1, 2026
  2. SECBIOVENTRIX, INC. Form D, filed Apr 24, 2026
  3. SECBIOVENTRIX, INC. Form D/A, filed Jul 8, 2025
  4. SECBIOVENTRIX, INC. Form D, filed Oct 15, 2024
  5. SECBIOVENTRIX, INC. Form D, filed Mar 29, 2024
  6. SECBIOVENTRIX, INC. Form D, filed Jan 6, 2020
  7. SECBIOVENTRIX, INC. Form D/A, filed Apr 30, 2019
  8. SECBIOVENTRIX, INC. Form D/A, filed Jan 30, 2019
  9. SECBIOVENTRIX, INC. Form D/A, filed Apr 26, 2018
  10. SECBIOVENTRIX, INC. Form D/A, filed Dec 19, 2017
  11. SECBIOVENTRIX, INC. Form D, filed Aug 30, 2017
  12. SECBIOVENTRIX, INC. Form D/A, filed Apr 5, 2017
  13. SECBIOVENTRIX, INC. filing history
  14. CompanyOur Company
  15. CompanyBioVentrix press releases